DE69833654T2 - Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren - Google Patents

Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren Download PDF

Info

Publication number
DE69833654T2
DE69833654T2 DE69833654T DE69833654T DE69833654T2 DE 69833654 T2 DE69833654 T2 DE 69833654T2 DE 69833654 T DE69833654 T DE 69833654T DE 69833654 T DE69833654 T DE 69833654T DE 69833654 T2 DE69833654 T2 DE 69833654T2
Authority
DE
Germany
Prior art keywords
phenylalanine
dichlorobenzenesulfonyl
prolyl
methylprolyl
cyanophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69833654T
Other languages
German (de)
English (en)
Other versions
DE69833654D1 (de
Inventor
L. Philippe Rahway DURETTE
K. William Rahway HAGMANN
Malcolm Rahway MACCOSS
G. Sander Rahway MILLS
A. Richard Rahway MUMFORD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714316.8A external-priority patent/GB9714316D0/en
Priority claimed from GBGB9800680.2A external-priority patent/GB9800680D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69833654D1 publication Critical patent/DE69833654D1/de
Application granted granted Critical
Publication of DE69833654T2 publication Critical patent/DE69833654T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Optical Filters (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE69833654T 1997-05-29 1998-05-29 Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren Expired - Fee Related DE69833654T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4785697P 1997-05-29 1997-05-29
US47856P 1997-05-29
GB9714316 1997-07-07
GBGB9714316.8A GB9714316D0 (en) 1997-07-07 1997-07-07 Biarylalkanoic acids as cell adhesion inhibitors
US6683197P 1997-11-25 1997-11-25
US66831P 1997-11-25
GB9800680 1998-01-14
GBGB9800680.2A GB9800680D0 (en) 1998-01-14 1998-01-14 Biarylalkanoic acids as cell adhesion inhibitors
PCT/US1998/010951 WO1998053817A1 (en) 1997-05-29 1998-05-29 Biarylalkanoic acids as cell adhesion inhibitors

Publications (2)

Publication Number Publication Date
DE69833654D1 DE69833654D1 (de) 2006-04-27
DE69833654T2 true DE69833654T2 (de) 2006-12-14

Family

ID=27451677

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833654T Expired - Fee Related DE69833654T2 (de) 1997-05-29 1998-05-29 Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren

Country Status (8)

Country Link
EP (1) EP1017382B1 (enExample)
JP (1) JP2001517245A (enExample)
AT (1) ATE318841T1 (enExample)
AU (1) AU726585B2 (enExample)
CA (1) CA2291762A1 (enExample)
DE (1) DE69833654T2 (enExample)
ES (1) ES2257808T3 (enExample)
WO (1) WO1998053817A1 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69820614T2 (de) * 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough Entzündungshemmende tyrosin-derivate
JP2001517246A (ja) 1997-06-23 2001-10-02 田辺製薬株式会社 α▲下４▼β▲下１▼媒介細胞接着の阻止剤
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) * 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
EP1150951A1 (en) * 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
EA006301B1 (ru) 1999-01-22 2005-10-27 Элан Фармасьютикалз, Инк. Ацильные производные, используемые для лечения опосредованных vla-4 расстройств
AR035476A1 (es) * 1999-01-22 2004-06-02 Elan Pharm Inc Compuestos heteroarilo y heterociclicos con anillo fusionado, los cuales inhiben la adhesion de leucocitos mediada por vla-4, composiciones farmaceuticas, el uso de las mismas para la manufactura de un medicamento y un metodo para fijar vla-4 en una muestra biologica
EP1150997A1 (en) * 1999-01-25 2001-11-07 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
GB2354440A (en) * 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
RS50470B (sr) 1999-08-13 2010-03-02 Biogen Idec Ma Inc. Inhibitori ćelijske adhezije
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
KR100522344B1 (ko) * 1999-12-06 2005-10-20 에프. 호프만-라 로슈 아게 4-피리미디닐-ｎ-아실-ｌ-페닐알라닌
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
CN1196682C (zh) * 1999-12-06 2005-04-13 霍夫曼-拉罗奇有限公司 4－吡啶基－n－酰基－l－苯丙氨酸
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
DE19962936A1 (de) 1999-12-24 2001-06-28 Bayer Ag Neue beta-Aminosäureverbindungen als Integrinantagonisten
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
EP1332132B1 (en) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
EP1322309B1 (en) * 2000-09-29 2008-08-13 Neurogen Corporation High affinity small molecule c5a receptor modulators
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
KR20040105740A (ko) 2002-02-25 2004-12-16 엘란 파마슈티칼스, 인크. 염증 치료제의 투여 방법
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
EP1546089A2 (en) 2002-08-09 2005-06-29 TransTech Pharma Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
EP1558250A4 (en) 2002-10-30 2006-11-02 Merck & Co Inc GAMMA AMINOAMIDE MODULATORS OF THE CHEMOKIN RECEPTOR ACTIVITY
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
US7459472B2 (en) 2003-08-08 2008-12-02 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
BRPI0509803A (pt) 2004-04-13 2007-09-18 Incyte Corp derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina
FR2869904B1 (fr) * 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
EP2298356A3 (en) 2004-07-08 2011-08-10 Elan Pharmaceuticals, Inc. Multivalent VLA-4 antagonists comprising polymer moieties
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
JP5101512B2 (ja) 2005-09-29 2012-12-19 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４によって媒介される白血球接着を阻害するピリミジニルアミド化合物
US7727996B2 (en) 2005-09-29 2010-06-01 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
NZ570679A (en) 2006-02-27 2011-01-28 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4
AR060901A1 (es) * 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
PT2370442E (pt) 2008-11-26 2013-06-27 Pfizer 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina
SG172857A1 (en) 2009-02-09 2011-08-29 Supergen Inc Pyrrolopyrimidinyl axl kinase inhibitors
ES2602902T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
CN102448928B (zh) 2009-05-28 2014-10-01 诺华股份有限公司 作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
EP2956445A1 (en) 2013-02-14 2015-12-23 Novartis AG Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
WO2015136468A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
WO2018085578A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW223629B (enExample) * 1992-03-06 1994-05-11 Hoffmann La Roche
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5707985A (en) * 1995-06-07 1998-01-13 Tanabe Seiyaku Co. Ltd. Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators
US6248713B1 (en) * 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
JP2002501537A (ja) * 1997-05-29 2002-01-15 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのスルホンアミド類

Also Published As

Publication number Publication date
ATE318841T1 (de) 2006-03-15
AU726585B2 (en) 2000-11-09
EP1017382A1 (en) 2000-07-12
DE69833654D1 (de) 2006-04-27
EP1017382B1 (en) 2006-03-01
CA2291762A1 (en) 1998-12-03
EP1017382A4 (en) 2000-08-30
ES2257808T3 (es) 2006-08-01
WO1998053817A1 (en) 1998-12-03
JP2001517245A (ja) 2001-10-02
AU7703198A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
DE69833654T2 (de) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
DE69824037T2 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6271252B1 (en) Cyclic amino acid derivatives as cell adhesion inhibitors
DE69025952T2 (de) Antithrombotische peptide und pseudopeptide
US6403584B1 (en) Substituted nipecotyl derivatives as inhibitors of cell adhesion
US6291511B1 (en) Biarylalkanoic acids as cell adhesion inhibitors
US6353099B1 (en) Substituted ureas as cell adhesion inhibitors
DE69812890T2 (de) Alpha-9 integrin antagonisten sowie diese enthaltende anti-inflammatorisch wirkende zusammensetzungen
WO1999020272A1 (en) Azapeptide acids as cell adhesion inhibitors
JP2002512625A (ja) 細胞接着阻害薬としての複素環アミド化合物
EP0998282A1 (en) Sulfonamides as cell adhesion inhibitors
US6191171B1 (en) Para-aminomethylaryl carboxamide derivatives
WO1999026923A1 (en) Para-aminomethylaryl carboxamide derivatives
US6221888B1 (en) Sulfonamides as cell adhesion inhibitors
WO1999026922A1 (en) Substituted pyrrole derivatives as cell adhesion inhibitors
US6020347A (en) 4-substituted-4-piperidine carboxamide derivatives
US20020193399A1 (en) N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
GB2354440A (en) Aryl amides as cell adhesion inhibitors
WO1999025685A1 (en) 4-substituted-4-piperidine carboxamide derivatives
DE69426897T2 (de) Antithrombotisch wirkende azacycloalkyl-alkanoyl-peptide und-pseudopeptide
AU2002255775B2 (en) Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
US6482840B2 (en) Substituted cyclic amidine derivatives as inhibitors of cell adhesion
US6855708B2 (en) N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6734311B2 (en) Substituted amidine derivatives as inhibitors of cell adhesion
US6069163A (en) Azapeptide acids as cell adhesion inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee